Detailed Information

Cited 30 time in webofscience Cited 32 time in scopus
Metadata Downloads

A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer

Authors
Oh, Do-YounCha, YongjunChoi, In-SilYoon, So-YoungChoi, In KeunKim, Jee HyunOh, Sang CheulKim, Chang DuckKim, Jae SunBang, Yung-JueKim, Yeul Hong
Issue Date
Feb-2010
Publisher
SPRINGER
Keywords
Gemcitabine; S-1; Pancreatic cancer; Palliative
Citation
CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.65, no.3, pp 527 - 536
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume
65
Number
3
Start Page
527
End Page
536
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15190
DOI
10.1007/s00280-009-1059-9
ISSN
0344-5704
1432-0843
Abstract
To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, with at least one measurable lesion were eligible for the study. Gemcitabine at a dose of 1,000 mg/m(2) was intravenously given over 30 min on days 1 and 8, while S-1 at a dose of 40 mg/m(2) was orally given twice daily from day 1 to 14, and the cycle was repeated every 3 weeks. The objective response rate, which was assessed according to RECIST criteria, was the primary end point. A total of 38 patients were enrolled between June 2006 and June 2007. The median number of treatment courses was 5.5 (range 1-22). Thirty-four patients were evaluable for response. Although no complete response was seen, partial responses were achieved in 11 patients, resulting in an overall response rate of 32% [95% confidence interval (CI) 17-48%]. The median response duration was 6.0 months (95% CI 4.6-8.3 months), the median time-to-progression was 5.4 months (95% CI 2.9-8.0 months), and the median overall survival was 8.4 months (95% CI 5.7-11.1 months). The major grade 3/4 hematologic toxicities were neutropenia (39.5%), leukopenia (15.8%), thrombocytopenia (2.6%), and anemia (7.9%). The major grade 3/4 non-hematologic toxicities included anorexia (10.5%), stomatitis (2.6%), rash (7.9%), fatigue (7.9%) and hyperbilirubinemia (5.3%). Gemcitabine and S-1 combination chemotherapy was effective and tolerable in patients with unresectable pancreatic cancer.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Oh, Sang Cheul photo

Oh, Sang Cheul
Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE